The report provides a detailed analysis essential for establishing a methyclothiazide production plant. It encompasses all critical aspects necessary for methyclothiazide production, including the cost of methyclothiazide production, methyclothiazide plant cost, methyclothiazide production costs, and the overall methyclothiazide production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a methyclothiazide production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Methyclothiazide is a thiazide diuretic that is used to treat hypertension. It is used alone or combined with other antihypertensives. It is utilised in edema associated with conditions like congestive heart failure, hepatic cirrhosis, renal dysfunction, or hormone therapies like corticosteroids or estrogen. It works by stopping the Na-Cl cotransporter in the distal convoluted tubule of the kidneys, which blocks sodium and chloride reabsorption. This increases their excretion along with water to promote diuresis, reduce fluid overload, and lower blood pressure through both renal and potential vascular smooth muscle relaxation effects. Its oral dosages range from 2.5-5 mg daily for hypertension and up to 10 mg for edema in adults, with monitoring required for electrolyte imbalances like hypokalemia. Its common side effects include dizziness, muscle cramps, nausea, or serious risks, including dehydration and hyperglycemia.
The market for methyclothiazide is fuelled by the global rise in hypertension and cardiovascular diseases. The rise in ageing populations, obesity, urbanisation, sedentary lifestyles, and increased public health awareness contributes to its market growth. Its strong demand in regions like North America and rapid expansion in Asia-Pacific, because of improving healthcare infrastructure, boost its market.
The industrial methyclothiazide procurement is affected by low-margin generic, along with API supply chain disruptions from geopolitical issues or limited suppliers. The strict regulatory compliance costs, like GMP and FDA standards, and prolonged government tender processes influence its market dynamics. The demand for forecasting inaccuracies, transportation delays, and heavy reliance on a few distributors further affects its sourcing strategies.
Raw Material for Methyclothiazide Production
According to the methyclothiazide production plant project report, the key raw materials used in the production of methyclothiazide include 5-chloro-2,4-disulfamoylaniline, urea, methyl iodide, sodium hydride, and chloroacetaldehyde.
Production Process of Methyclothiazide
The extensive methyclothiazide production cost report consists of the following major industrial production process:
- From 5-chloro-2,4-disulfamoylaniline: The production process of methyclothiazide starts with the cyclisation of 5-chloro-2,4-disulfamoylaniline using urea. This results in the formation of 7-sulfamoyl-6-chloro-3-oxo-3,4-dihydro-2H-1,2,4-benzothiadiazine-1,1-dioxide. This intermediate is then reacted with methyl iodide in the presence of sodium hydride, using DMF as solvent, to introduce the 2-methyl group, forming an intermediate. This goes through hydrolysis with sodium hydroxide, which is subsequently treated with chloroacetaldehyde to introduce the 3-(chloromethyl) group, to form methyclothiazide as the final product.
Methyclothiazide has the molecular formula of C9H11Cl2N3O4S2 and a molecular weight of 360.2 g/mol. It appears as a white to off-white crystalline powder with a high melting point of around 225 degree Celsius. It shows limited aqueous solubility at about 11.2 mg/L (pH 7), slight solubility in ethanol and other alcohols, and good solubility in polar organic solvents like acetone and dimethylformamide. It shows its moderate lipophilicity with a logP value of 1.42. It features a 1,2,4-benzothiadiazine-7-sulfonamide core with a 6-chloro substitution and a 3-methyl group, and lacks chiral centres. It has a weakly acidic pKa around 9.4 due to the sulfonamide moiety, contributing to its pharmacological stability and bioavailability in oral diuretic formulations.
